Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by themagicboxon Nov 18, 2020 8:55am

186 Views

Post# 31920962

RE:RE:To bad

I agree, Pez. Consolidation inherently doesnt affect value ofc, but the lower float means it can become more volatile in either direction. But given that every dip is getting bought up, uplisting will open the doors to instos in a way that ATE has never had before. My prediction is that they drop another NR in the next 2 weeks prior to december 1.

Inthepez wrote: The notion that "reverse split = universally bad" with no other context is so flawed. And frankly dumb as cumster the dumpester, which prettt f*cking dumb.

Thegambler26 wrote:
I like this stock but RS never turns out well, will take much longer to make money here now. Moving over to NOU for now alot more exciting things happening there. Will be back here in the summer.